Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets

摘要: Palliative chemotherapy is the mainstay of treatment advanced gastric carcinoma (GC). Monoclonal antibodies including trastuzumab, ramucirumab, and pembrolizumab have been shown to provide additional benefits. However, clinical outcomes are often unpredictable they can vary widely among patients. Currently, no biomarker available for predicting response in individual patient except human epidermal growth factor receptor 2 (HER2) amplification programmed death-ligand 1 (PD-L1) expression effectiveness trastuzumab pembrolizumab, respectively. Multi-platform molecular analysis cancer, GC, may help identify predictive biomarkers guide selection therapeutic agents. Molecular classification GC by The Cancer Genome Atlas Research Network Asian Group expected targets biomarkers. Complementary characterization profiling genomic sequencing tumor DNA. Initial patients with gastroesophageal demonstrates that ratio progression-free survival (PFS) on profile (MP)-based PFS prior exceeds 1.3, suggesting potential value MP guiding individualized therapy. Future strategies aiming integrate tumors agents achieving goal personalized indicated.